Pincer Approach to Gastrosplenic Ligament in Robotic Total Gastrectomy for Gastric Cancer

Nishi, Masaaki; Wada, Yuma; Yoshikawa, Kozo; Takasu, Chie; Tokunaga, Takuya; Nakao, Toshihiro; Kashihara, Hideya; Yoshimoto, Toshiaki; Nakasu, Chiharu; Shimada, Mistuo

doi:10.1007/s11605-022-05356-3

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The surgical techniques of RS and LS in our institute were reported previously. [22][23][24] We performed extended total gastrectomy (TG) with lower mediastinal LN dissection or extended proximal gastrectomy (PG) with lower mediastinal LN dissection for Siewert II/III AEG. Intraoperative gastric ber was routinely employed.…”

Section: Introductionmentioning

confidence: 99%

Utility of robotic surgery for Siewert type II/III adenocarcinoma of esophagogastric junction: transhiatal robotic versus laparoscopic approach

Nishi

Wada

Yoshikawa

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Robotic surgery (RS) has been rapidly adopted for gastric cancer and adenocarcinoma of the esophagogastric junction (AEG). However, the utility of RS for Siewert type II/III AEG remains unclear. Methods Forty-one patients who underwent either transhiatal RS (n = 15) or laparoscopic surgery (LS) (n = 26) for Siewert type II/III AEG were enrolled in this study. The surgical outcomes of the two groups were compared. Results In the entire cohort, there were no significant intergroup differences in the operative time, blood loss volume, or number of retrieved lymph nodes. The length of the postoperative hospital stay was shorter in the RS group than in the LS group (14.20 ± 7.10 days vs. 18.73 ± 17.82 days, respectively; p = 0.0388). The morbidity rate (Clavien–Dindo grade ≥ 2) was similar between the groups. In the Siewert II cohort, there were no significant intergroup differences in short-term outcomes. In the entire cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (91.67% vs. 91.48%, N.S.) or 3-year disease-free survival rate (91.67% vs. 91.78%, N.S.), respectively. Likewise, in the Siewert type II cohort, there was no significant difference between the RS and LS groups in the 3-year overall survival rate (80.00% vs. 93.33%, N.S.) or 3-year disease-free survival rate (80.00% vs. 94.12%, N.S.), respectively. Conclusions Transhiatal RS for Siewert II/III AEG was safe and contributed to similar short-term and long-term outcomes compared with LS.

show abstract

Section: Introductionmentioning

confidence: 99%